uniQure (NASDAQ:QURE) Given its average rating of “Moderate Buy” by analysts

Shares of uniQure (NASDAQ:QURE – Get Free Report) have received an average rating of “Moderate Buy” from the seven research firms currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average one-year price target among brokers who have covered the stock in the past year is $24.75.

A number of research analysts have recently commented on the stock. Mizuho lowered their price target on shares of uniQure from $7.00 to $6.00 in a research note on Wednesday, May 8. Goldman Sachs Group downgraded shares of uniQure from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $63.00 to $8.00 in a research report on Thursday, February 29. upgraded shares of uniQure to a “sell” rating in a research report on Friday, March 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of uniQure in a research report on Wednesday, May 8.

Read our latest analysis on QUERE

uniQure shares fell 0.8%

Shares of QUERE opened at $4.72 on Wednesday. uniQure has a 52-week low of $4.25 and a 52-week high of $21.00. The company has a market cap of $229.15 million, a price-to-earnings ratio of -0.76 and a beta of 0.98. The company’s 50-day simple moving average is $4.91 and its 200-day simple moving average is $5.77. The company has a debt-to-equity ratio of 0.70, a quick ratio of 9.27 and a current ratio of 9.39.

uniQure (NASDAQ:QURE – Get Free Report) last reported its quarterly results on Tuesday, May 7. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) ($0.05). uniQure had a negative net margin of 1,562.22% and a negative return on equity of 121.60%. The company had revenue of $8.49 million during the quarter, compared to analyst estimates of $2.58 million. On average, analysts predict that uniQure will post -4.61 earnings per share for the current year.

Institutional trading in uniQure

Several major investors have recently made changes to their positions in the company. Headlands Technologies LLC bought a new position in uniQure in the third quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. increased its stake in uniQure by 222.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,258 shares of the biotech company worth $42,000, after purchasing an additional 4,315 shares during the last quarter. Nomura Holdings Inc. bought a new position in uniQure worth approximately $67,000 in the third quarter. Laurion Capital Management LP bought a new position in uniQure in the third quarter worth approximately $73,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in uniQure in the 4th quarter worth approximately $86,000. Institutional investors and hedge funds own 78.83% of the company’s shares.

About uniQure

(Get a free report

uniQure NV develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX, which has completed the pivotal Phase III HOPE-B study for the treatment of hemophilia B. The company is also developing AMT-130, a gene therapy that is in Phase I/II clinical trials for the treatment of Huntington’s disease.

Also see

Analyst recommendations for uniQure (NASDAQ:QURE)

Receive daily news and reviews for uniQure – Enter your email address below to receive a daily digest of the latest news and analyst ratings for uniQure and related companies with’s FREE daily email newsletter.

Back To Top